REVIEW

High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity

Marie Fitzgibbon, David P. Finn, PhD; Michelle Roche, PhD

Physiology (Ms Fitzgibbon and Dr Roche), and Pharmacology and Therapeutics (Dr Finn), School of Medicine, Galway Neuroscience Centre and Centre for Pain Research (Ms Fitzgibbon, Dr Finn, and Dr Roche), National Centre for Biomedical Engineering Science, National University of Ireland Galway, Ireland.

Correspondence: Michelle Roche, PhD, Physiology, School of Medicine, National University of Ireland, Galway, University Road, Galway, Ireland (michelle.roche@nuigalway.ie).

Abstract

Depression and pain are two of the most debilitating disorders worldwide and have an estimated cooccurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired health-related quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation of the hypothalamo-pituitary-adrenal axis, and neuroinflammation. However, the past decade has seen mounting evidence supporting a role for the endogenous cannabinoid (endocannabinoid) system in affective and nociceptive processing, and thus, alterations in this system may play a key role in reciprocal interactions between depression and pain. This review will provide an overview of the preclinical evidence supporting an interaction between depression and pain and the evidence supporting a role for the endocannabinoid system in this interaction.

Keywords: depression, pain, anandamide, cannabinoid, stress

Clinical Data Supporting Depression-Pain Comorbidity

Depression and pain are two of the most prevalent psychiatric and neurological disorders worldwide, and both are associated with significant disability, impaired health-related quality of life, and high mortality (Spitzer et al., 1995; Kvien, 2004; Scholich et al., 2012; Hassett et al., 2014). While each is considered a debilitating disorder in its own right, these disease entities frequently coexist, and it has been reported that this association may be as high as 80% of patients (Poole et al., 2009). For example, major depressive and bipolar disorder is associated with painful symptoms in up to 95% of patients (Grover et al., 2012; Maneeton et al., 2013; Nicholl et al., 2014). Similarly, patients suffering from inflammatory and neuropathic pain are up to 4.9 times more likely to develop depression or anxiety disorder than the general population (Hawker et al., 2011; Knaster et al., 2012; Emery et al., 2014; Lin et al., 2015). Patients exhibiting comorbid depression and pain do not respond as effectively to pharmacological treatment, and this comorbidity is more disabling and expensive to both patients and society than either condition alone (Emptage et al., 2005; Gameroff and Olfson, 2006). Furthermore, it has also been found that the severity of depression directly correlates with increased severity of pain symptomatology (Khongsaengdao et al., 2000). However, it should be noted that an intricate relationship exists between depression and pain such that although pain is commonly reported by depressed patients, examination of pain thresholds to various stimuli such as cold, heat, and pressure have been shown to be reduced, increased, or unchanged (Ben-Tovim and Schwartz, 1981; Lautenbacher et al., 1999; Gormsen et al., 2004; Bar et al., 2005; Boettger et al.,...
effects which depend on the modality and intensity of the stimulus. Thus, given the complex interaction between affect and pain, and the high comorbidity of depression-pain, greater understanding of the neurobiological mechanisms underlying the association is warranted to develop more efficacious treatment strategies. There have been several studies investigating the role of neural substrates, including neuroanatomical organization, neurotransmission, neurotrophins, dysregulation of the hypothalmo-pituitary-adrenal (HPA) axis, and inflammation, to name but a few, in the interaction between affect and nociceptive processing (for review, see Blackburn-Munro, 2004; Goesling et al., 2013; Walker et al., 2014). A full review of the role of each of these substrates is beyond the scope of this review. However, increased evidence has indicated a role for a further substrate, the endogenous cannabinoid (endocannabinoid) system, in affective and nociceptive responding (for reviews, see Finn, 2010; Ashton and Moore, 2011; Gorzałka and Hill, 2011; Rani Sagar et al., 2012; Hillard and Liu, 2014; Jennings et al., 2014; Borsuk et al., 2015) and as such, alterations in this system may provide a common mechanism by which depression and pain coexist. Preclinical animal models provide a valuable means of investigating potential neurobiological substrates that may underlie the association between depression and pain. As such, this review will provide an overview of the preclinical evidence supporting an interaction between depression and pain, the evidence supporting a role for the endocannabinoid system in this interaction, and the potential mechanisms through which the endocannabinoid system may mediate effects on affect and nociceptive processing.

Preclinical Animal Models Support Depression-Pain Interactions

Animal Models of Depression Exhibit Altered Nociceptive Responding

Several animal models of depression based on genetics, stress, lesion, and pharmacological manipulation have been shown to exhibit alterations in nociceptive responding (for review, see Li, 2015), supporting the clinical finding of an association between depression and pain. For example, in rats, the chronic mild stress model of depression has been shown to display a reduced nociceptive threshold to cold (Bardin et al., 2009; Bravo et al., 2012; Bravo et al., 2014) and mechanical (Bardin et al., 2009; Imbe et al., 2012) stimuli and an increased threshold to noxious thermal stimuli (Shi et al., 2010). Furthermore, both inflammatory (Gameiro et al., 2005; Rivat et al., 2010; Wang et al., 2013) and neuropathic (Bravo et al., 2012) pain behavior are enhanced in chronic stress models of depression. Similarly, we and others have shown that the Wistar-Kyoto (WKY) rat, a stress hyperresponsive rat strain with a depressive-like phenotype, exhibits thermal hyperalgesia (Burke et al., 2010), visceral hyperalgesia to colorectal distension (Gibney et al., 2010; Gosselin et al., 2010; O’Malley et al., 2010), enhanced formalin-evoked inflammatory pain behavior (Burke et al., 2010; Rea et al., 2014), and enhanced mechanical allodynia following peripheral nerve injury (neuropathic pain) (Zeng et al., 2008; del Rey et al., 2011). Reserpine-induced monoamine depletion has long been known to result in depressive-like behavior, and recent evidence has demonstrated accompanying thermal alldynia (Liu et al., 2014), as well as pronounced and long-lasting mechanical hyperalgesia and allodynia, and cold alldynia (Nagakura et al., 2009; Arora et al., 2011). Thus, this model has been proposed as a possible rodent model of fibromyalgia (Nagakura et al., 2009). Furthermore, recent work from our group has demonstrated that the olfactory bulbectomised rat, a lesion model of depression, exhibits increased sensitivity to mechanical and thermal stimuli in the von Frey, acetone drop, hot plate, and tail flick tests (Burke et al., 2010, 2013), increased inflammatory pain responding in the formalin test (Burke et al., 2010), and enhanced neuropathic pain responding following spinal nerve ligation (Burke et al., 2013, 2014). Thus, taken together, several animal models of depression have been shown to exhibit altered nociceptive thresholds and enhanced inflammatory and neuropathic pain behavior, mimicking effects observed clinically.

Animal Models of Chronic Pain Exhibit Depressive-Like Behavior

Depressive- and anxiety-like behavior, as assessed by multiple paradigms, has been reported in a wide variety of preclinical models of chronic pain (for review, see Yalcin et al., 2014; Li, 2015). For example, peripheral or spared nerve injury in mice induces a pronounced mechanical allodynia accompanied by the development of depressive-like behavior as determined by enhanced immobility in the forced swim test (FST) (Goncalves et al., 2008; Norman et al., 2010; Wang et al., 2011). Similarly, rodents subjected to the chronic constriction injury model of neuropathic pain exhibit reduced sucrose preference (Dellarole et al., 2014) and increased immobility in the FST (Hu et al., 2009; Jesse et al., 2010; Fukuhara et al., 2012; Zhao et al., 2014), indicating the development of anhedonia and behavioral despair, hallmarks of depressive-like behavior. In the complete Freund’s adjuvant model of inflammatory pain, both mice and rats exhibited depression-like behavior in the FST (Maciel et al., 2013, Borges et al., 2014) and tail suspension test (Maciel et al., 2013) and anxiety-related behavior in the elevated plus-maze, open field test, and social interaction test (Parent et al., 2012; Borges et al., 2014). Such changes in affective processing in chronic pain models have been shown to occur later than the development of enhanced somatosensory perception. For example, in neuropathic pain models, alterations in emotional behavior have been observed 4 to 8 weeks post nerve injury (Suzuki et al., 2007; Yalcin et al., 2011), but not prior to this (2-4weeks) when mechanical allodynia/hypersensitivity is observed (Kontinen et al., 1999; Hasnie et al., 2007). These studies highlight the development of depressive- and anxiety-like behavior in models of neuropathic or inflammatory pain and suggest that pathological alterations induced by persistent nociceptive input to brain regions that process both pain and affect may account, at least in part, for comorbid depressive-like behavioral changes.

Animal models that replicate the clinical scenario are important for in-depth investigation of the possible neurobiological substrates that may mediate the association between depression and chronic pain. Although the cause of this coexistence remains somewhat elusive, as highlighted earlier, common anatomical substrates and neurobiological mediators, including neurotransmitters, neurotrophins, neuroendocrine alterations, and inflammatory mediators, have been identified, any or all of which may alter neural functioning in key brain regions involved in regulating emotional and nociceptive processing (for review, see Blackburn-Munro, 2004; Maletic and Raison, 2009; Anderson et al., 2012; Goesling et al., 2013; Meerwijk et al., 2013; Jennings et al., 2014; Walker et al., 2014; Doan et al., 2015). Increasing evidence has highlighted an important role for the endocannabinoid system in modulating emotional and
nociceptive processing, and thus this system may play a key role in the association between pain and depression.

The Endocannabinoid System

The plant Cannabis sativa has been used as a medicine throughout the world for several thousand years, with reports of its use in treating painful symptoms appearing as early as 2600 BC. The principal psychoactive ingredient of Cannabis sativa, delta-9-tetrahydrocannabinol (Δ9-THC), was first identified in 1964 (Gaoni and Mechoulam, 1964), and subsequent studies to understand its mechanism of action led to the discovery of the endogenous cannabinoid (endocannabinoid) system. This endocannabinoid system consists of the cannabinoid receptors (CB1 and CB2) (Devane et al., 1988; Matsuda et al., 1990; Munro et al., 1993), their naturally occurring endogenous ligands (the best characterized of which are N-arachidonoylthanolamine, or anandamide [AEA] (Devane et al., 1992) and 2-arachidonylglycerol (2-AG) (Mechoulam et al., 1995)), and the enzymes involved in their biosynthesis and degradation. Other endocannabinoid ligands have also been identified, including oleamide (Leggett et al., 2004), O-arachidonyl ethanolamine (virodhamine) (Porter et al., 2002), 2-arachidonoyl glycerol ether (noladin ether) (Hanus et al., 2001), and N-arachidonoyl-dopamine (Huang et al., 2002), although their physiological role has not been examined in detail.

Endocannabinoid biosynthesis occurs on demand via hydrolysis of cell membrane phospholipid precursors. AEA is formed from the precursor N-arachidonoylphosphatidylethanolamine due to the hydrolytic activity of the phospholipase D enzyme NAPE-PLD (Di Marzo et al., 1994; Sugiuara et al., 1996), while fatty acid amide hydrolase (FAAH) is the primary enzyme responsible for the metabolism of this endocannabinoid (Cravatt et al., 1996). In comparison, the main biosynthetic pathway for 2-AG involves the hydrolysis of the membrane phospholipid phosphatidylinositol by phospholipase C, producing 1,2-diacylglycerol, which is then converted to 2-AG by diacylglycerol lipase (Prescott and Majerus, 1983, Sugiuara et al., 1995). 2-AG is primarily metabolized by monoylacylglycerol lipase (MAGL) (85%) (Blankman et al., 2007), although other enzymes including cycooxygenase-2 (Yu et al., 1997; Kozak et al., 2000), lipoxigenase (van der Stelt et al., 2002), ABDH6 (serine hydrolase o/l-hydrolase domain), and ABDH12 (Blankman et al., 2007), have also been shown to play a role.

Upon release, endocannabinoids bind and activate the G-protein coupled receptors CB1 and/or CB2. CB receptors are highly expressed on presynaptic neurons throughout the human and rodent brain (Herkenham, 1991; Tsou et al., 1998; Mackie, 2008), the activation of which results in inhibition of cyclic AMP, activation of mitogen-activated protein kinase, inhibition of N- and P/Q-type voltage-activated Ca2+ channels, and induction of inwardly rectifying K+ currents, with the resultant inhibition of neurotransmitter release (Demuth and Molleman, 2006). CB receptors have also been shown to be expressed on glia and a wide range of peripheral tissues, though at lower levels than observed on neurons (Galiegue et al., 1995; Carlisle et al., 2002; Osei-Hyiaman et al., 2005; Cavoanto et al., 2007; Kota, 2007). In contrast, CB receptors are widely distributed in peripheral tissues and organs, with a particularly high density on immune cells and tissues (Munro et al., 1993; Berdyshnev, 2000; Sugiuara et al., 2000), including on glia within the brain, with enhanced expression observed under neuromflammatory conditions (Carlisle et al., 2002; Nunez et al., 2004; Rock et al., 2007). Accumulating evidence has also indicated that the CB receptor is also expressed on subsets of neurons within the brain (Van Sickle et al., 2005; Gong et al., 2006; Baek et al., 2008; Zhang et al., 2014) and thus also modulates neurotransmission (Roche and Finn, 2010; Atwood et al., 2012; Kim and Li, 2015). Endocannabinoids also have affinity for and activity at other receptors, namely the transient receptor potential vaniloid 1, peroxisome proliferator-activated receptors, GPR55, and GPR119 (Huang et al., 2002, Overton et al., 2006; Sun et al., 2006; Ryberg et al., 2007). Activity at these receptors has been proposed to account, at least partially, for some of the differential effects observed with potent selective cannabinoid agonists and pharmacological modulators of endocannabinoid tone.

Because of the distribution of the endocannabinoid system throughout spinal and supraspinal regions, it is in a prime position to regulate neurophysiological activities such as affective and nociceptive processing. This has been a very active area of research over the past decade, with a number of excellent reviews synthesizing the data supporting a role for the endocannabinoid system in modulating mood and nociception (for review, see Ashton and Moore, 2011; Gorzalka and Hill, 2011; Rani Sagar et al., 2012; Hillard and Liu, 2014; Ulugol, 2014; Boychuk et al., 2015). However, no review to date has examined the evidence that may support a role for the endocannabinoid system as a link between depression and pain, and thus the remainder of this review aims to collate and synthesize these data.

The Role of the Endocannabinoid System In Depression-Pain Interactions

Clinical Evidence

Several lines of evidence have demonstrated alterations in the endocannabinoid system in chronic pain (Richardson et al., 2008; Kaufmann et al., 2009) and in psychiatric patients (Gobbi et al., 2005; Hill and Gorzalka, 2005; Koethe et al., 2007). For example, various polymorphisms of CB1 and CB2 receptors have been identified in patients with major depression and bipolar disorder (Monteleone et al., 2010; Minocci et al., 2011; Mitjans et al., 2012; Mitjans et al., 2013) with a single nucleotide polymorphism in the CB2 receptor reported to enhance the risk of treatment resistance in depression (Domschke et al., 2008) and the development of anhedonic depression following early life trauma (Agrawal et al., 2012). Similarly, genetic alterations in the CB2 receptor and FAAH have also been identified in patients with pain associated with migraine, Parkinson’s disease, and irritable bowel syndrome (Juhasz et al., 2009; Park et al., 2011; Greenbaum et al., 2012). In addition, serum levels of endocannabinoids have been reported to be reduced in both depressed patients (Hill et al., 2008c, 2009b) and chronic pain patients (Fichna et al., 2013). A recent study has reported enhanced plasma 2-AG levels and increased CB1 and CB2, mRNA expression on blood lymphocytes in osteoarthritic patients (La Porta et al., 2015). A significant positive correlation was observed between 2-AG levels, pain, and depression, and a negative correlation of 2-AG with quality of life and visual memory was observed (La Porta et al., 2015). In addition, CB1 receptor expression was positively correlated with depression scores, while CB2 receptor expression was correlated with pain scores. These data indicate that key components of the endocannabinoid system are upregulated in human osteoarthritis with significant correlations with pain and emotional symptoms. In addition to visual loss and sensory deficits, neuropathy is also associated with significant pain (altered threshold responding and symptoms of neuropathic pain), depression, and increased plasma levels of 2-AG and...
AEA (Pellkofer et al., 2013). This study evaluated if a correlation existed between pain threshold and levels of endocannabinoids, demonstrating a considerable negative correlation between the plasma levels of 2-AG and mechanical pain thresholds in these patients, although this study did not evaluate if an association also existed with depressed mood. While the data suggest a possible association between pain, depression, and the endocannabinoid system in osteoarthritis and neuromyelitis optica patients, further clinical studies are required to determine if alterations in the genetics, levels, and activity of the endocannabinoid system exist in other patient groups exhibiting depression-pain comorbidity.

There has been a paucity of clinical studies directly investigating the role or activity of cannabinoids in depression-pain interactions; however, enhanced mood and improved quality of life have been reported in studies investigating the analgesic efficacy of cannabinoid-based therapies (Table 1). For instance, cannabis intake has been reported to improve muscle and nerve pain as well as depression and anxiety symptomatology in a group of HIV patients (Woolridge et al., 2005). Improvements in anxiety and overall distress have been reported in patients with advanced cancer in whom pain symptoms were managed by daily adjunctive administration of Cesamet (nabilone, a Δ9-THC analogue) for 30 days (Maida et al., 2008). Similarly, a randomized, double blind, placebo-controlled trial, which examined the therapeutic benefit of nabilone in terms of pain management and quality of life improvement in patients with fibromyalgia, identified significant pain relief and alleviation of anxiety symptoms after 4 weeks of therapy (Skrabek et al., 2008). In addition, a retrospective evaluation investigating the efficacy of nabilone for the management of concurrent disorders in seriously mentally ill correctional populations identified significant amelioration of symptoms related to posttraumatic stress disorder as well as a subjective improvement in chronic pain (Cameron et al., 2014). Furthermore, a multicenter retrospective survey of patients with chronic central neuropathic pain or fibromyalgia who were prescribed oral Δ9-THC (dronabinol), supplemental to existing medication, reported improved symptoms of both anxiety and depression after 7 months of treatment as assessed by the Hospital Anxiety and Depression Scale (Weber et al., 2009). Although Sativex (1:1 ratio of Δ9-THC:cannabidiol), indicated for resistant spasticity and pain in multiple sclerosis, has not yet been directly associated with significant mood changes, patients have reported improvements in overall quality of life following 16 weeks of treatment (Vermersch, 2011). In a separate randomized control clinical trial evaluating the effect of Sativex in patients with chronic painful diabetic neuropathy, patients with comorbid depression displayed significant improvements in total pain score in comparison with nondepressed counterparts (Selvarajah et al., 2010). Collectively, the above studies suggest that when coexistent, both depression/anxiety and pain respond to exogenously administered cannabinoids, although it remains to be determined if the effects are mediated by common or parallel mechanisms. Recent evidence has demonstrated enhanced amygdala activity and reduced functional connectivity between the amygdala and somatosensory cortex correlate with Δ9-THC-mediated reductions in the unpleasantness to ongoing pain (Lee et al., 2013), suggesting that the amygdala may provide a common neural circuit for the association between emotional responding and pain.

### Preclinical Evidence

Despite numerous reports of altered endocannabinoid signaling in various animal models of pain (Lim et al., 2003; Zhang et al., 2003; Walczak et al., 2005; Mitirirattanakul et al., 2006) and mood-related behavior (Vinod et al., 2012; Marco et al., 2014; Navarra et al., 2014), there is limited direct evidence available identifying alterations in endocannabinoid function in animal models of coexistent depressive and pain behavior (Tables 2 and 3).

#### Table 1. Clinical Studies Demonstrating Effects of Cannabinoid-Based Therapies on Symptoms of Comorbid Depression and Pain

| Drug | Pain Measurement | Depression/Anxiety Measurement | Outcomes in Pain | Outcomes in Depression/Anxiety | Reference |
|------|------------------|---------------------------------|------------------|---------------------------------|-----------|
| HIV  | Cannabis         | Pilot questionnaire             | Pilot Questionnaire | muscle, ↓ nerve pain, headaches | ↓ anxiety, depression | Woolridge et al. (2005) |
| Cancer pain | Nabilone (Cesamet®) | ESAS MSE            | ESAS             | ↓ pain score, ↓ pain, ↓ anxiety, overall stress | ↓ anxiety, ↓ pain, ↓ anxiety | Maida et al. (2008) |
| Fibromyalgia | Nabilone | VAS FIQ               | Anxiety          | ↓ pain score, ↓ pain, ↓ anxiety, overall stress | ↓ anxiety, ↓ pain, ↓ anxiety | Skrabek et al. (2008) |
| Mentally ill offenders | Nabilone | Self-reported pain severity | PCL-C GAF        | ↓ pain, ↓ PTSD symptoms | ↓ QOL | Cameron et al. (2014) Vermersch (2011) |
| Multiple sclerosis-related resistant spasticity | Sativex (Δ9-THC, cannabidiol) | NRS spasticity score | QOL             | ↓ spasticity | ↓ QOL | Vermersch (2011) |
| Chronic central neuropathic pain, fibromyalgia | Δ9-THC | VRS, NRS, PDI             | SF-12, QLIP, HADS, | ↓ pain, pain intensity | ↑ QOL, ↓ depression, ↓ anxiety | Weber et al. (2009) |
| Painful diabetic peripheral neuropathy | Sativex (Δ9-THC, cannabidiol) | VAS                 | HADS, QOL        | ↓ pain (only in patients with baseline depression) | ↑ QOL | Selvarajah et al. (2010) |

Abbreviations: ESAS, Edmonton symptom assessment system; FIQ, fibromyalgia impact questionnaire; GAF, Global Assessment of Functioning; HADS, hospital anxiety and depression scale; HIV, human immunodeficiency virus; MSE, morphine sulphate equivalent; NRS, numerical rating scale; PDI, pain disability index; PCL-C, Posttraumatic Checklist-Civilian version; PTSD, posttraumatic stress disorder; QLIP, quality of life; QOL, quality of life; SF-12, short form-12; VAS, visual analog scale; VRS, verbal rating scale.
The WKY rat is a genetically stress-sensitive strain of rat that exhibits a depression- and anxiety-related phenotype (Pare and Redei, 1993) and heightened nociceptive behavioral responding in several paradigms (Zeng et al., 2008; Burke et al., 2010). Characterization of the endocannabinoid system in WKY rats has revealed higher levels of FAAH and CB, receptor coupling and lower levels of AEA in the frontal cortex and hippocampus when compared with Wistar rats (Vinod et al., 2012). Furthermore, enhancing AEA tone by pharmacologically inhibiting FAAH activity resulted in an attenuation of depressive-like behavior (sucrose preference test and FST) in WKY rats (Vinod et al., 2012). Recent studies in our laboratory have identified alterations in the endocannabinoid system concurrent with enhanced formalin-evoked nociceptive behavior in the WKY rat (Rea et al., 2014) (Table 2). More specifically, we found that in WKY rats, intraplantar administration of the noxious inflammatory pain stimulus formalin resulted in a significant reduction in AEA in the rostral ventromedial medulla (RVM), a component of the descending pain pathway synonymous with pain facilitation and/or inhibition, an effect that was not observed in Sprague Dawley (SD) counterparts. Intraplantar administration of formalin increased levels of 2-AG in the RVM of SD rats, an effect not observed in WKY animals. Furthermore, exposure to formalin induced significant increases in mRNA expression of NAPE-PLD and diacylglycerol lipase-alpha, precursors of AEA and 2-AG, respectively, in the RVM of SD rats, an effect not observed in the WKY strain. Pharmacological

Table 2. Endocannabinoid-Mediated Effects/Changes on Affective and Nociceptive Behavior in Animal Models

| Depression/ Affective Model | Nociceptive Effects                        | Cannabinoid-based drugs | Endocannabinoid-related changes/effects | Reference                  |
|-----------------------------|--------------------------------------------|-------------------------|----------------------------------------|----------------------------|
| Anxiety-stratified (EPM, mouse) | ↑ formalin-evoked nociceptive responding in anxious and non-anxious | Δ⁹-THC, agonist CB, antagonist | Δ⁹-THC ↓ nociception in both anxious and non-anxious mice, Rimonabant blocked effects of Δ⁹-THC | Takahashi et al. (2003) |
| WKY rat                     | ↑ formalin-evoked nociceptive responding   | URB597 AM251 FAAH inhibitor CB antagonist | Systemic URB597 ↓ nociception Systemic AM251 ↑ nociception AM251 within RVM blocked effect of URB597 | Rea et al. (2014) |
| Repeated FST in SD and WKY rat | Stress ↓ formalin-evoked nociceptive responding in SD Stress ↓ formalin-evoked nociceptive responding in WKY | FAAH inhibitor MAGL inhibitor | ↑ MAGL mRNA in spinal cord of SD ↓ AEA in amygdala of SD No change in MAGL mRNA in spinal cord of WKY No change AEA in amygdala of WKY | Jennings et al. (2015) |
| CUS, mouse                  | ↓ latency to respond in HPT                | URB597 JZL184 FAAH inhibitor, MAGL inhibitor | URB597 ↓ anxiety (EPM, LD) JZL184 ↓ anxiety (LD) Both ↓ thermal hyperalgesia | Lomazzo et al. (2015) |
| CUS, mouse                  | Chronic mechanical hyperalgesia following NGF | URB597 JZL184 FAAH inhibitor, MAGL inhibitor | URB597 ↓ hyperalgesia No change with JZL184 | Lomazzo et al. (2015) |

Abbreviations: AEA, anandamide; 2-AG, 2-arachidonoylglycerol; CUS, chronic unpredictable stress; EPM, elevated plus maze; FAAH, fatty acid amino hydrolase; DAGL-α, diacylglycerol lipase-alpha; HPT, hot plate test; LD, light-dark box; MAGL, monacrylglycerol lipase; NAPE-PLD, N-acyl phosphatidylethanolamine-specific phospholipase D; NGF, nerve growth factor; RVM, rostral ventromedial medulla; SD, Sprague Dawley; WKY, Wistar-Kyoto.
studies were carried out to evaluate the functional significance of the alterations in the endocannabinoid system in WKY rats in response to formalin. Enhancing endogenous AEA tone following systemic administration of the FAAH inhibitor URB597 attenuated formalin-evoked hyperalgesic responding in WKY rats, while in comparison, CB1 receptor antagonism was associated with augmentation of nociceptive responding. Furthermore, CB1 receptor blockade within the RVM attenuated the reduction in nociceptive behavior induced by URB597 in WKY rats. In comparison, pharmacological manipulation of the endocannabinoid system in SD rats did not alter formalin-evoked nociceptive responding (Rea et al., 2014). These findings indicate a causative role of endocannabinoid dysregulation in hyperalgesic behavior associated with negative affect, and moreover identify a role for AEA-induced activation of CB1 receptors in the RVM as a mediator of pain suppression in animal subjects predisposed to anxiety and depression. In addition to its role in influencing responsivity of WKY rats to noxious stimuli in the absence of stress, we have also shown very recently that the endocannabinoid system may also play a role in the differential effects of repeated homotypic stress on inflammatory pain-related behavior in WKY vs SD rats (Jennings et al., 2015). Specifically, repeated forced swim stress exposure prolonged and attenuated formalin-evoked nociceptive behavior in SD and WKY rats, respectively. These behavioral alterations were accompanied by differential effects of stress on AEA levels in the amygdala and MAGL expression in the spinal cord between SD and WKY rats (Jennings et al., 2015). These data indicate that changes in the tone of the endocannabinoid system in the amygdala and spinal cord may underlie the differential effects of stress on inflammatory pain behavior between SD and WKY rats.

The chronic unpredictable stress (CUS) model of depression has been shown to exhibit thermal hyperalgesia in the hotplate test (Lomazzo et al., 2015), cold allodynia (Bravo et al., 2012), exacerbated trigeminovascular nociception (Zhang et al., 2013), inflammatory hyperalgesia in response to formalin administration (Shi et al., 2010), and persistent mechanical hyperalgesia following nerve growth factor administration (Lomazzo et al., 2015). Exposure to CUS has been shown to result in site-specific alterations in the endocannabinoid system, notably a downregulation of CB1 receptors, reduction in 2-AG levels and increased FAAH levels in the hippocampus (Hill et al., 2005; Reich et al., 2009), an increase in CB1 receptor density in the hypothalamus and striatum and increased CB2 receptor density in the prefrontal cortex (Hill et al., 2008a; McLaughlin et al., 2013), a reduction in 2-AG-mediated retrograde synaptic transmission in the hippocampus (Zhong et al., 2014), and a reduction in FAAH levels in the hypothalamus, prefrontal cortex, hippocampus, and striatum (Hill et al., 2008a). Depressive-like behaviors in the CUS model have been shown to be attenuated by endocannabinoid-modulating pharmacological agents, including the MAGL inhibitor JZL184 (Zhong et al., 2014; Zhang et al., 2015). Only one study to date has examined the effect of endocannabinoid modulation on affective and pain responding in CUS-exposed mice. Pretreatment with the FAAH inhibitor, URB597, or MAGL inhibitor, JZL184, which enhanced endogenous levels of AEA and 2-AG, respectively, significantly attenuated CUS-induced anxiety-related behavior in the light-dark box and concurrent thermal hyperalgesia (Lomazzo et al., 2015). Long-lasting widespread mechanical hyperalgesia,
induced by intramuscular administration of nerve growth factor to CUS rats, was effectively reduced by URB597, but not JZL184 (Lomazzo et al., 2015). These data demonstrate an important role for AEA signaling in anxiety- and pain-related behavior in stress-exposed mice.

In addition to the evidence supporting a role for the endocannabinoid system in enhanced nociception observed in models of depression, alterations in endocannabinoid signaling have also been observed in animal models of chronic pain with comorbid alteration in affective responding (Table 2). A recent report by Racz and colleagues (2015) has revealed a prominent role of CB1-mediated events in affective behavior induced by neuropathic pain. In this study, partial sciatic nerve ligation (PNL) was employed to induce a model of neuropathic pain in wild-type and CB1-/- mice. Wild-type and CB1-/- mice exhibited mechanical allodynia following PNL. However, evaluation of anxiety- (light-dark test and the elevated zero-maze) and depressive-like (sucrose preference test) behavior 4 to 7 weeks following PNL revealed deficits in affective responding in CB1-/- but not wild-type, mice (Racz et al., 2015). Thus, these data demonstrate that functionally active CB1 receptors confer resilience to pain-related anxiety/depression, highlighting a protective role for CB1 receptors against the emotional consequences of neuropathic pain. In a similar fashion, La Porta et al. (2015) recently investigated the role of the endocannabinoid system in affective and cognitive manifestations in an animal model of osteoarthritis. This study revealed that the anxiety-related behavior of osteoarthritic mice, identified in the elevated plus maze, was enhanced in CB1-/- and absent in CB1-/- mice, indicating differential effects of CB1 and CB2 receptors in mediating the affective dimension of pain in the model. Similar to effects in a neuropathic model (Racz et al., 2015), the data would indicate that CB1 receptors confer resilience, while CB2 receptors confer susceptibility to the development of arthritis-related anxiety. The authors suggest and provide some support that the differential effects of CB1 and CB2 receptors may be mediated by alterations in HPA axis functionality and responses (La Porta et al., 2015). In addition, this study also demonstrated that acute pharmacological blockade of CB1 or CB2 receptors ameliorated both the nociceptive and affective dimension of pain in the model (La Porta et al., 2015). Taken together, the data suggest that cortico-limbic endocannabinoid signaling is a key modulator of different osteoarthritis pain manifestations.

Only one study to date has investigated the role of CB1 receptors in the interaction between neuropathic pain and affective behavior. The chronic constriction injury model of neuropathic pain results in mechanical hypersensitivity and depressive-like behavior (immobility in the FST) in mice (Hu et al., 2009). Both depressive-like behavior and mechanical hyperalgesia following constriction injury were significantly attenuated by systemic administration of the CB1 receptor agonist GW405833, effects that were not observed in sham-operated animals. Furthermore, such behavioral effects were superior to administration of a tricyclic antidepressant, first line treatment for depression and chronic pain (Hu et al., 2009). The precise mechanism by which CB1 receptor agonism may elicit anxiolytic and antidepressant-like effects was not evaluated; however, given the well-recognized role for inflammatory processes in mediating chronic pain, it is possible that CB1 receptor activation attenuates such responses, preventing the development of central sensitization and mechanical allodynia and the associated increase in neuronal input to affective supraspinal sites. Further studies are required to evaluate this theory.

Intraperitoneal administration of a dilute concentration of lactic or acetic acid has been shown to induce abdominal stretching/writhing (visceral pain behavior), an effect associated with a reduction in feeding and hedonic behaviors (pain-depressed behavior). Evaluation of the role of the endocannabinoid system in mediating pain-stimulated and pain-depressed/suppressed responses in this model has revealed that genetic antagonism of CB1 receptors enhances acid-induced writhing (visceral pain stimulated behavior) and augments acid-induced reductions in feeding (Miller et al., 2011). In contrast, CB1 receptor agonism using Δ-9-THC and CP55940 dose dependently inhibits acid-stimulated stretching while eliciting either no effect (Miller et al., 2012) or exacerbating (Kwilasz and Negus, 2012) acid-induced depression of feeding and scheduled controlled/intracranial self-stimulation in rats. Thus, under these conditions, potent synthetic cannabinoids such as Δ-9-THC and CP55940 may elicit differential effects on visceral pain (attenuated) and pain-related depressive (exacerbated) behavior. However, the FAAH inhibitor URB597 exhibits a dose-related and CB1 receptor-mediated decrease in acid-stimulated stretching and suppression of feeding (Miller et al., 2012; Kwilasz et al., 2014). Furthermore, URB597 also elicits a delayed but significant attenuation of acid-induced suppression of intracranial self-stimulation, an effect occurring independent of CB1, or CB1/2 mediation (Kwilasz et al., 2014). Taken together, these data indicate a role for CB1 receptors in mediating acid-induced visceral pain, with a possible common and/or alternative endocannabinoid mechanism mediating the associated anhedonic/depressive-like behavior.

Overall, despite the limited data, evidence suggests a prominent role for the endocannabinoid system in the interaction between depression and pain, although whether the effects are mediated by the same or parallel neuroanatomical pathways remains to be determined.

Mechanisms By Which The Endocannabinoid System May Modulate Depression And Pain Interactions

While the exact mechanism(s) by which the endocannabinoid system may influence emotional and nociceptive processing remains undetermined, this system is known to elicit potent modulatory effects on neurotransmission, neuroendocrine, and inflammatory processes, all known to be altered in both depression and chronic pain. Presented here is an overview of how the endocannabinoid system may modulate affective and pain processing via interacting with these systems.

Neurotransmitters

GABA and Glutamate

GABA- and glutamatergic neurotransmission are well recognized as important mediators in affect and nociceptive processing, and alterations in these systems have been demonstrated in both depression and chronic pain (for review, see Kendall et al., 2005; Rea et al., 2007). There are an increasing number of studies demonstrating that glutamatergic and GABAergic signaling play an important role in mediating the depressive symptoms associated with chronic pain. For example, ketamine, an NMDA receptor antagonist, attenuated depressive-like behavior following spared nerve injury without altering injury-induced hypersensitivity (Wang et al., 2011), while AMPAkines (which augment AMPA receptor function) have been shown to attenuate both pain hypersensitivity and associated depressive-like behavior
in models of chronic inflammatory and neuropathic pain (Le et al., 2014). Furthermore, facilitation of glutamatergic transmission through AMPA receptors in the nucleus accumbens, a brain region involved in reward, resulted in attenuation of depression-like behavior in an animal model of neuropathic pain (Goff er et al., 2013). Despite a recognized role for the GABAergic system in emotional and pain processes, to our knowledge few studies have investigated the role of this system in affect-pain interactions to date. One such study has reported that GABAergic receptor activation in the RVM blocked formalin-induced hyperalgesia produced upon removal from an aversive elevated plus maze (stressor) (Cornelio et al., 2012). In addition, Quintero and colleagues (2011) have also identified that repeated forced swim stress-induced inflammatory hyperalgesia is initiated by decreased and delayed GABA release and GABAergic receptor activation and maintained by increased glutamate release and NMDA activation at the spinal cord level (Suarez-Roca et al., 2008).

CB1 receptors are expressed at a particularly high density on presynaptic nerve terminals of GABAergic and glutamatergic synapses in cortical and limbic areas of the brain associated with stress, emotional response, and pain modulation (Herkenham et al., 1990; Katona et al., 2001; Domenici et al., 2006; Wittmann et al., 2007). Endocannabinoids have been shown to exert behaviorial effects via CB1 receptor agonist and resultant presynaptic inhibition of GABAergic and glutamatergic transmission (Meng et al., 1998; Millan, 2002) in supraspinal and spinal regions (Ulugol, 2014). In addition, glutamatergic neurotransmission is known to enhance endocannabinoid formation and subsequent CB1 receptor activation (Galante and Diana, 2004). Thus, complex bidirectional interaction exists between the endocannabinoid-glutamatergic-GABAergic systems. Several studies have demonstrated that CB1 modulation of GABAergic signaling is important in nociceptive (Manning et al., 2003; Naderi et al., 2005; Fernia-Andrade et al., 2009) and emotional (Haller et al., 2007; Naderi et al., 2008; Rossi et al., 2010; Rey et al., 2012; Reich et al., 2013) processing. Although it would appear intuitive, it is unknown if endocannabinoid modulation of GABA and/or glutamate plays a role in depression-pain interactions. However, we have demonstrated that CB1 receptors play an important role in mediating analgesia in response to acute stress (contextual fear conditioning) (Finn et al., 2004; Butler et al., 2008) and demonstrated an important role for GABAergic and glutamatergic signaling in the basolateral amygdala in mediating this effect (Rea et al., 2014). Thus, endocannabinoid modulation of GABAergic and glutamatergic tone can mediate stress-pain interactions and therefore may play a prominent role in coexistent psychiatric and pain disorders.

Monoamines

In addition to the treatment of depression, monoamine-based antidepressants are now regarded as first-line therapy for fibromyalgia and neuropathic pain. The monoaminergic system has been proposed as a common neural substrate for depression-pain associations. In accordance, a number of preclinical studies have demonstrated beneficial effects of modulating monoaminergic tone on depression associated with chronic pain and vice versa. For example, recent studies have demonstrated that chronic administration of 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene, which increases serotonergic neurotransmission by inhibiting presynaptic serotonin transport, attenuates mechanical allodynia and depressive-like behavior in an animal model of neuropathic pain (Gai et al., 2014). Furthermore, chronic imipramine treatment reduces depressive-like behavior, but not hyperalgesia, in a rat model of neuropathic pain, effects mediated by increasing the neurotrophin BDNF (Yasuda et al., 2014). In addition, direct administration of a BDNF inducer (4-MC) into the brain attenuated thermal hyperalgesia and depressive-like behavior following nerve injury (Fukuhara et al., 2012; Ishikawa et al., 2014). The spinal serotonergic system has been shown to participate in the thermal hyperalgesia response in an animal model of depression, the olfactory bulbectomized rat (Rodriguez-Gaztelumendi et al., 2014). We have shown recently chronic amitriptyline treatment elicits an antidepressant-like effect and potently attenuates nerve injury-induced mechanical and cold allodynia in the bullectomy model of depression (Burke et al., 2015). Thus, enhancing monoaminergic tone, and consequently central BDNF expression, modulates pain-depression behaviors.

Several lines of evidence have demonstrated that chronic antidepressant administration modulates endocannabinoid signaling (Hill et al., 2006; 2008b; Mato et al., 2010; Smaga et al., 2014), which underlie at least in part the mechanism by which these pharmacological agents modulate affective and nociceptive processes. Furthermore, endocannabinoid-induced modulation of serotonergic, noradrenergic, and dopaminergic transmission has been thoroughly investigated in several excellent reviews (Haj-Dahmane and Shen, 2011; Melis and Pistis, 2012; KirilI et al., 2013). CB1 receptors are highly expressed on serotonergic, noradrenergic, and dopaminergic neurons and play an important role in the regulation of monoaminergic activity. Local and systemic administration of exogenous CB1 receptor agonists significantly increases serotonin (Bambico et al., 2007), noradrenaline (Jentsch et al., 1997; Oropesa et al., 2005; Page et al., 2007, 2008), and dopamine (Cheer et al., 2004; Solinas et al., 2006) levels in discrete brain regions that mediate emotional and nociceptive processing. Increasing endogenous levels of AEA and 2-AG through systemic administration of FAAH or MAGL inhibitors, respectively, has also been shown to enhance serotonergic and dopaminergic activity (Gobbi et al., 2005; Seif et al., 2011), and FAAH inhibition in the PFC increases serotonergic neuronal firing in the dorsal raphe nucleus (McLaughlin et al., 2012). In addition, endocannabinoids can inhibit the activity of monoamine oxidase (Fisar, 2010), the enzyme responsible for the metabolism of monoamines, which may also contribute to the increasing synaptic availability of the monoamines. Endocannabinoid activation of the CB1 receptor has been shown to control the function and expression of specific serotonin receptors, namely 5-HT2A, 5-HT2C, and 5-HT3 in discrete regions of the CNS (Aso et al., 2009; Moranta et al., 2009; Zavitsanou et al., 2010; Franklin et al., 2013). Furthermore, spinal noradrenergic deactivation is associated with compromised analgesic effects of CB1 agonism on formalin-evoked inflammatory pain (Gutierrez et al., 2003), while CB1 receptor activation results in attenuation of enhanced serotonergic firing in the dorsal raphe following nerve injury, an effects accompanied by antinociception (Palazzo et al., 2006). Taken together, these data demonstrate that cannabinoids modulate nociceptive tone, in part through modulation of noradrenergic and serotonergic systems. Thus, endocannabinoid-induced enhancement of monoaminergic tone may modulate emotional and nociceptive processes and thus the interaction between depression and pain.

Opioids

Numerous studies have characterized the causative role and therapeutic potential of opioidergic signaling in affective and nociceptive processing (for review, see Maletic and Raison, 2009; Lutz and Kieffer, 2013). Furthermore, alterations in opioid signaling in key brain regions such as the amygdala have
been reported in a chronic pain model that exhibits comorbid anxiety-related behavior (Narita et al., 2006). Acute morphine administration attenuated both mechanical allodynia and anxiety-related behavior in the complete Freund’s adjuvant model of inflammatory pain (Parent et al., 2012). A very substantial body of evidence is now available to suggest that the endocannabinoid and opioidergic systems interact in therapeutically beneficial ways. CB, and μ-opioid receptors are highly colocalized in neurons in areas of the brain associated with emotional and pain processing such as the caudate putamen, periaqueductal gray, and spinal cord (Rodriguez et al., 2001; Salio et al., 2001; Wilson-Poe et al., 2012). Co-administration of opioids and cannabinoids results in synergistic and bidirectional antinoceptive effects in several animal models (Cichewicz et al., 1999; Cichewicz and McCarthy, 2003; Tham et al., 2005; Roberts et al., 2006; Smith et al., 2007; Wilson et al., 2008; Wilson-Poe et al., 2013). In addition, increasing endocannabinoid tone has been shown to attenuate withdrawal symptoms in morphine-dependent animals (Smith et al., 2007; Wilson et al., 2008; Shahidi and Hasanein, 2011). Interestingly, cross tolerance also exists between these neuromodulatory systems. For example, decreases in the analgesic effects of Δ^2-THC have been identified in morphine-tolerant animals and vice versa (Thorat and Bhargava, 1994). Furthermore, inhibition of opioid signalling (via κ-opioid receptors) attenuates the antidepressant-like effect of rimonabant (CB, receptor antagonist/inverse agonist) in the FST (Lockie et al., 2011), and conversely the antidepressant-like effects of κ-opioid receptor antagonism are attenuated by the CB, receptor antagonist/inverse agonist AM251 (Bird et al., 2009). Although further studies are required, collectively these findings suggest a regulatory role of the endocannabinoid system on opioid transmission, which may underlie the maintenance of coexistent depression-pain processes.

**Neuroendocrine Activity – HPA Axis**

Dysregulation of the HPA axis has been implicated in the pathophysiology of both depression and pain disorders for decades (for review, see Bomholt et al., 2004; Vierck, 2006; Maric and Adzic, 2013; Belvederi Murri et al., 2014) and thus has also been proposed as a possible mediator in the depression-pain dyad (for review, see Blackburn-Munro, 2004). Several clinical studies have identified altered HPA axis activity in patients exhibiting symptoms of both depression and pain. For example, a cross-sectional study of patients with advanced breast cancer revealed increasing plasma cortisol levels that positively correlated with symptoms of depression and pain (Thornton et al., 2010). However in patients with fibromyalgia, enhanced cortisol release and dysregulation of HPA function associates with depressive, but not pain, symptoms, implying possible diverging mechanisms for both affective and nociceptive processing in this condition (Wingenfeld et al., 2010). Preclinical evidence of this reciprocity is also evident in an experimental model of gastritis, which is associated with gastrointestinal inflammation, pain, and anxiety- and depressive-like behaviors in rats (Luo et al., 2013). These behavioral alterations are accompanied by dysregulation of the HPA axis, characterized by increased expression of corticotrophin-releasing factor (CRF) mRNA and reduced expression of glucocorticoid receptor in the hypothalamus and increased plasma levels of corticosterone (Luo et al., 2013). Increased expression of CRF has also been reported in the paraventricular nucleus of the hypothalamus and dorsal raphe nucleus of WKY rats and animals preexposed to neonatal maternal separation, respectively (Bravo et al., 2011), two models of depression and associated hyperalgesia. Pharmacological blockade of CRF1 following intraamygdalar infusion of the CRF1 antagonist CP376395 inhibits hyperalgesic responding to colorectal distension in WKY rats, an effect not observed following glucocorticoid receptor or mineralocorticoid receptor antagonism (Johnson et al., 2012). Furthermore, the hyperalgesic visceromotor response to phasic colorectal distension following repeated water avoidance stress has been shown to be attenuated by CRF1 antagonism (Laracuente et al., 2008). In addition, systemic or intraamygdalar injection of the CRF1 receptor antagonist NBI22914 blocks anxiety-related and nocifensive behavior in a rat model of arthritis (Li et al., 2017). Thus, the CRF-HPA stress axis has been shown to play a key role in affective and/or nociceptive processing.

Several lines of evidence now support an important role for the endocannabinoid system as a modulator of HPA axis function and vice versa (for review, see Finn, 2010; Riebe and Wotjak, 2011; Hill and Tasker, 2012). The majority of evidence collected to date would suggest that basal HPA activity is under tonic inhibitory control by CB receptors. This has been shown in numerous reports where genetic deletion or pharmacological blockade of the CB receptor in vivo enhances expression of CRF and reduces glucocorticoid receptor expression in the hypothalamus and pituitary gland, respectively (Cota et al., 2007), and increases circulating levels of corticosterone and adrenocorticotropic hormone (Barna et al., 2004; Cota et al., 2007; Steiner et al., 2008). In addition, stress-induced increases in CRF expression in the paraventricular nucleus of the hypothalamus and the basolateral amygdala, as well as corticosterone secretion, are effectively blocked by pharmacological enhancement of endocannabinoid levels (Patel et al., 2004; Hill et al., 2009a; Bedse et al., 2014; Roberts et al., 2014), thus implying a role for endocannabinoid-CB receptor signaling in diminished hyperactivity of the HPA axis. Furthermore, recent evidence has shown that CRF1 activation in the amygdala induces FAAH and reduces AEA levels, an effect associated with anxiety-related behavior (Gray et al., 2015). Given the important role of the amygdala in affective modulation of pain, it is possible that CRF-mediated FAAH activation in this region may also modulate nociceptive possessing and associated emotional alterations. While there have been a few studies examining endocannabinoid-HPA axis effects in mediating the effects of the stress response (Hill et al., 2011; Roberts et al., 2014), to date no study has investigated if cannabinoid-mediated alterations of the HPA axis underlie alterations in nociceptive and/or affective behavior observed in depression-pain comorbidity.

**Neuro-Inflammatory Processes**

Increasing evidence indicates a potent and prominent interaction between inflammation, depression, and pain (for review, see Walker et al., 2014). For instance, there is a high prevalence of depression among patients with inflammatory pain disorders such as fibromyalgia, arthritis, and irritable bowel disorder (Kappelman et al., 2014; Scheidt et al., 2014; Lin et al., 2015). In addition, patients receiving cytokine therapy for specific cancers and malignancies also develop depressive and/or painful symptomatology (Capuron and Ravdaud, 1999; Capuron et al., 2001; Nogueira et al., 2012). Furthermore, increases in serum and cerebrospinal fluid levels of proinflammatory cytokines have been widely reported in both depression (Tuglu et al., 2003; Knuth et al., 2014; Bay-Richter et al., 2015) and pain conditions (Koch et al., 2007; Ludwig et al., 2008; Kadetoff et al., 2012). Inflammatory processes have also been shown to underlie the interaction between...
depression and pain in several animal models. For instance, increased expression of proinflammatory cytokines, concomitant with depressive-like behavior, has been identified in animal models of inflammatory (Kim et al., 2012; Maciel et al., 2013) and neuropathic (Norman et al., 2010; Burke et al., 2014; Dellarcole et al., 2014; Zhou et al., 2015) pain. The innate inflammatory cascade has been shown to increase glutamate neurotransmission, central sensitization, and excitotoxicity, reduce BDNF and neurogenesis, and activate neurodegenerative cascades, events observed in both depression and pain conditions (for review, see Dantzer et al., 2011; Maes et al., 2011; Song and Wang, 2011; Zunszain et al., 2013; Walker et al., 2014). Over the past decade, a wealth of data has demonstrated an important role for the endocannabinoid system in modulating innate immune function and inflammatory processes (for review, see Alhouayek and Muccioli, 2012; Zajkowska et al., 2014; Henry et al., 2015). Interactions between the endocannabinoid system and inflammatory mediators has been shown to influence synaptic transmission and neuronal function (Rossi et al., 2014). Spinal cord injury has been shown to be associated with increased coexpression of CB1 receptors with chemokines CCL2, CCL3, and/or CCR2 in the hippocampus, thalamus, and periaqueductal grey, areas associated with affective pain responding (Knerlich-Lukoschus et al., 2011), and studies have also demonstrated that CB1-chemokine interactions in the periaqueductal grey can modulate nociceptive responding (Benamar et al., 2008). Pharmacological enhancement of endocannabinoid tone also modulates inflammatory effects in vivo. For example, the FAAH inhibitor URB597 and the MAGL inhibitor JZL184 attenuate inflammation-induced astrocyte and microglial activation (Katz et al., 2015) and neuroinflammatory processes (Kerr et al., 2012, 2013; Henry et al., 2014). Furthermore, Zoppi and colleagues (2011, 2014) have demonstrated that pharmacological activation of CB1, or CB2 receptors attenuates, while genetic deletion of these receptors augments, repeated stress-induced proinflammatory responses in the frontal cortex. In addition, several studies have demonstrated that the analgesic effects of cannabinoids in chronic inflammatory and neuropathic pain are at least partially mediated by modulation of inflammatory responses (Burgos et al., 2012; Wilkerson et al., 2012; Burston et al., 2013; Lu et al., 2015). While there are no studies to date investigating if cannabinoid modulation of inflammatory processes underlies coexistent depression and pain behavior, the above findings suggest a potential role for cannabinoid-mediated immunomodulation in the pathogenesis and treatment of co-occurring depression and pain.

Conclusion and Future Directions

This review has provided an overview of the clinical and preclinical evidence supporting an association between depression and pain and vice versa. While a number of neural substrates have been proposed to underlie this association, this review provides a synthesis of the data supporting the contention that comorbid depression and pain may be mediated at least in part via dysregulation of the endocannabinoid system. Targeting the endocannabinoid system for therapeutic benefit has been an ever-expanding area of research with more than 150 clinical trials during the past decade evaluating the effects of cannabinoids in pain and psychiatric disorders (International Clinical Trials Registry Platform). While no study to date has specifically evaluated the effects of cannabinoids on depression-pain comorbidity, several have examined effects on mood and quality of life in patients receiving cannabinoid-based pharmaceuticals for analgesic purposes (Maida et al., 2008; Skrabek et al., 2008; Weber et al., 2009; Cameron et al., 2014), providing a basis for further study in this area. However, many of these cannabinoids are potent CB1 receptor agonists (Δ9-THC derivatives), an effect that may limit their usefulness in psychiatric conditions due to the associated adverse CNS effects. Cannabidiol has been shown to limit the adverse CNS effects associated with CB1 receptor agonists, and Sativex (1:1 Δ9-THC:cannabidiol) has been shown to reduce chronic pain and improve mood (Selvarajah et al., 2010; Vermersch, 2011). Thus, combination therapy may be a beneficial treatment strategy for depression-pain comorbidity. As highlighted throughout this review, modulation of endogenous cannabinoid tone provides an alternative to direct CB1 receptor agonism and although still in the early stages of clinical investigation, FAAH inhibitors such as PF-04457845 have demonstrated safety and tolerability in patients, although no effect on pain associated with osteoarthritis was reported (Fluggins et al., 2012). However, this inhibitor is currently under clinical investigation for treatment of cannabis withdrawal, PTSD, and Tourette syndrome (International Clinical Trials Registry Platform), the results from which will provide important clinical data on the effect of FAAH inhibition on affective responding. Further clinical studies will provide greater insight into alterations and the role of the endocannabinoid system in the association between depression and pain.

Preclinical models that encapsulate the clinical scenario are particularly useful in gaining greater understanding of the neurobiology underlying depression-pain interactions. This review has presented the evidence to date demonstrating alterations in various components of the endocannabinoid system in models of depression-pain comorbidity and highlighted a particular role for AEA and CB1 receptors in mediating and modulating the affective and nociceptive processes in these models. However, research in this area is still in its infancy, and this review highlights the gaps in the knowledge and outstanding questions that remain to be addressed. For example, there have been limited data examining the role of other components of the endocannabinoid system on depression-pain interactions (2-AG, CB1, peroxisome proliferator-activated receptors, etc.), whether the endocannabinoid modulation of affect and nociception occur through the same or parallel pathways, and the mechanism by which the endocannabinoid system may mediate its effects (neurotransmitters, HPA axis, inflammation, or a combination). Furthermore, it is unknown if the role of the endocannabinoid system in chronic pain associated with depression is the same or different from altered affective processing associated with chronic pain conditions. Such studies are essential if we are to move towards a more comprehensive understanding of the neurobiology underlying the association between these pain and depression and fully explore the potential clinical efficacy of targeting the endocannabinoid system for resolution of these comorbid conditions.

Acknowledgments

This work was supported by funding received from Molecular Medicine Ireland Clinical & Translational Research Scholars Programme.

Statement of Interest

None.

References

Agrawal A, Nelson EC, Littlefeld AK, Bucholz KK, Degenhardt L, Henders AK, Madden PA, Martin NG, Montgomery
GW, Pergadia ML, Sher KJ, Heath AC, Lynskey MT (2012) Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression. Arch Gen Psychiatry 69:732–740.

Alhouayek M, Muccioli GG (2012) The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 18:615–625.

Anderson G, Maes M, Berk M (2012) Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Adv Protein Chem Struct Biol 88:27–48.

Arora V, Kuhad A, Tiwari V, Chopra K (2011) Curcumin ameliorates reserpine-induced pain-depression dyad: behavioral, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology 36:1570–1581.

Ashton CH, Moore PB (2011) Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 124:250–261.

Aso E, Renoir T, Mengod G, Ledent C, Hamon M, Maldonado R, Lanfumey L, Valverde O (2009) Lack of CB1 receptor activity impairs serotonergic negative feedback. J Neurochem 109:935–944.

Atwood BK, Straiker A, Mackie K (2012) CB(2) cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. Neuropharmacology 63:514–523.

Baek JH, Zheng Y, Darlington CL, Smith PF (2008) Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 128:961–967.

Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27:11700–11711.

Bar KJ, Zheng Y, Darlington CL, Smith PF (2008) Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 128:961–967.

Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27:11700–11711.

Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L, Guillemin GJ, Erhardt S, Brundin L (2015) A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun 43:110–117.

Barn A, Zelen D, Arsowszki AC, Ledent C (2004) The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 75:2959–2970.

Borges G, Neto F, Mico JA, Berrocoso E (2014) Reversal of monoarthritis-induced affective disorders by diclofenac in rats. Anesthesiology 120:1476–1490.

Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103–1110.

Boychunk DG, Goddard G, Mauro G, Orellana MF (2015) The effectiveness of cannabinoids in the management of chronic non-malignant neuropathic pain: a systematic review. J Oral Facial Pain Headache 29:7–14.

Braid D, Capurro V, Zani A, Rubino T, Viganò D, Parolaro D, Sala M (2009) Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 157:844–853.

Bravo JA, Dinan TG, Cryan JF (2011) Alterations in the central CRF system of two different rat models of comorbid depression and functional gastrointestinal disorders. Int J Neuropsychopharmacol 14:666–683.

Bravo L, Mico JA, Rey-Brea R, Perez-Nieves B, Leza JC, Berrocoso E (2012) Depressive-like states heighten the aversion to painful stimuli in a rat model of comorbid chronic pain and depression. Anesthesiology 117:613–625.

Bravo L, Torres-Sanchez S, Alba-Delgado C, Mico JA, Berrocoso E (2014) Pain exacerbates chronic mild stress-induced changes in noradrenergic transmission in rats. Eur Neuropsychopharmacol 24:996–1003.

Burgos E, Gomez-Nicola D, Pascual D, Martin MF, Nieto-Sampedro M, Goicoechea C (2012) Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol 682:62–72.

Burke NN, Hayes E, Calpin P, Kerr DM, Moriarity O, Finn DP, Roche M (2010) Enhanced nociceptive responding in two rat models of depression associated with alterations in monoamine levels in discrete brain regions. Neuroscience 171:1300–1313.

Burke NN, Geoghegan E, Kerr DM, Moriarity O, Finn DP, Roche M (2013) Altered neuropathic pain behavior in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala. Genes Brain Behav 12:705–713.

Burke NN, Kerr DM, Moriarity O, Finn DP, Roche M (2014) Mino- cycline modulates neuropathic pain behavior and cortical M1-M2 microglial gene expression in a rat model of depression. Brain Behav Immun 42:147–156.

Burke NN, Finn DP, Roche M (2015) Chronic administration of amitriptyline differentially alters neuropathic pain-related
behavior in the presence and absence of a depressieve-like phenotype. Behav Brain Res 278:193–201.

Burston JJ, Sagar DR, Shao P, Bai M, King E, Brailsford L, Turner JM, Hathway GJ, Bennett AJ, Walsh DA, Kendall DA, Lichtman A, Chapman V (2013) Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 8:e60440.

Butler RK, Rea K, Lang Y, Gavin AM, Finn DP (2008) Endocannabinoid-mediated enhanced pain of cervical angina in rats: opioid receptor dependency and molecular correlates. Pain 140:491–500.

Cameron C, Watson D, Robinson J (2014) Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol 34:559–564.

Capuron L, Ravva D (1999) Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state. N Engl J Med 340:1370.

Capuron L, Ravva A, Gualde N, Bosmans E, Dantzner R, Maes M, Neveu PJ (2003) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26:797–808.

Carlisle SJ, Marciano-Cabral F, Staab A, Ludwig C, Cabral GA (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2:69–82.

Cavuoto P, McAinch AJ, Hatzinikolas G, Janovska A, Game P, Wittet GA (2007) The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 364:105–110.

Cheer JF, Wassum KM, Heien ML, Phillips FE, Wightman RM (2004) Cannabinoids enhance second dopamine release in the nucleus accumbens of awake rats. J Neurosci 24:4393–4400.

Cichewicz DL, Martin ZL, Smith FL, Welch SP (1999) Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 289:859–867.

Cichewicz DL, McCarthy EA (2003) Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 304:1010–1015.

Cornelio AM, Nunes-de-Souza RL, Morgan MM (2012) Contribution of the rostral ventromedial medulla to post-anxiety induced hyperalgesia. Brain Res 1540:80–86.

Cota D (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23:507–517.

Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grubler C, Stallia J, Pasquali R, Lutz B, Stallia GK, Pagotto U (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148:1574–1581.

Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83–87.

Dantzner R, O'Connor JC, Lawson MA, Kelley KW (2011) Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36:426–436.

del Rey A, Yau HJ, Randolf A, Centeno MV, Wildmann J, Martina M, Besedovsky HO, Apkarian AV (2011) Chronic neuropathic pain-like behavior correlates with IL-1beta expression and disrupts cytokine interactions in the hippocampus. Pain 152:2827–2835.

Dellarole A, Morton P, Brambilla R, Walters W, Summers S, Bernardes D, Grilli M, Bethea JR (2014) Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling. Brain Behav Immun 41:65–61.

Demuth DG, Molleman A (2006) Cannabinoid signalling. Life Sci 78:549–563.

Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613.

Devane WA, Hanus L, Breuer A, Pertew KC, Stevenson LA, Griffin G, Gibson D, Mandalbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949.

Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piemelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686–691.

Doan L, Manders T, Wang J (2015) Neuroplasticity underlying the comorbidity of pain and depression. Neural Plast 2015:504691.

Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, Zieglsangberger W, Lutz B, Rammes G (2006) Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 26:5794–5799.

Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, Heindel W, Young R, Morris P, Arolt V, Deckert J, Susslow T, Baune BT (2008) Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18:751–759.

Emery PC, Wilson KG, Kowal J (2014) Major depressive disorder and sleep disturbance in patients with chronic pain. Pain Res Manag 19:35–41.

Emptage NP, Sturm R, Robinson RL (2005) Depression and comorbid pain as predictors of disability, employment, insurance status, and health care costs. Psychiatr Serv 56:468–474.

Fichna J, Wood JT, Papanastasiou M, Vadivel SK, Oprocha P, Salaga M, Sobczak M, Mokrowiecka A, Cyganiewicz AI, Zakrzewski PK, Malecka-Panas E, Krajewska WM, Koscielniak P, Makriyannis A, Storr MA (2013) Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS One 8:e85073.

Finn DP, Beckett SR, Richardson D, Kendall DA, Marsden CA, Chapman V (2004) Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. Eur J Neurosci 20:1496–1501.

Finn DP (2010) Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiology 215:629–646.

Fisar Z (2010) Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 381:563–572.

Franklin JM, Mathew M, Carrasco GA (2013) Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. Neurosci Lett 548:165–169.

Fukuhara K, Ishikawa K, Yasuda S, Kishishita Y, Kim HK, Kakuda T, Yamamoto M, Norii T, Ishikawa T (2012) Intracerebroventricular 4-methylcatechol (4-MC) ameliorates chronic pain associated with depression-like behavior via induction of...
brain-derived neurotrophic factor (BDNF). Cell Mol Neurobiol 32:971–977.

Gai BM, Bortolatto CF, Bruning CA, Zborowski VA, Stein AL, Zeni G, Nogueira CW (2014) Depression-related behavior and mechanical allodynia are blocked by 3-(4-fluorophenylselenyl)-2,5-di-phenylethene in a mouse model of neuropathic pain induced by partial sciatic nerve ligation. Neuropharmacology 79:580–589.

Galante M, Diana MA (2004) Group I metabotropic glutamate receptors inhibit GABA release at interneuron-Furkinje cell synapses through endocannabinoid production. J Neurosci 24:4865–4874.

Gallegue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54–61.

Gameiro GH, Andrade Ada S, de Castro M, Pereira LF, Tambeli CH, Gameiro J, Calabrese M, Machado IA, Carreiro D, Carayon P, A, Sousa N, Almeida A (2008) Neuropathic pain is associated with increased expression of cannabinoid receptors in the amygdala of the rat. Exp Neurol 213:48–56.

Gai BM, Bortolatto CF, Bruning CA, Zborowski VA, Stein AL, Zeni G, Nogueira CW (2014) Depression-related behavior and mechanical allodynia are blocked by 3-(4-fluorophenylselenyl)-2,5-di-phenylethene in a mouse model of neuropathic pain induced by partial sciatic nerve ligation. Neuropharmacology 79:580–589.

Gray JM, Vecchiarella HA, Morena M, Lee TT, Hermanson DJ, Kim AB, McLaughlin RJ, Hassan KI, Kuhne C, Wotjak CT, Deussing JM, Patel S, Hill MN (2015) Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci 35:3879–3892.

Greenbaum L, Tegeder I, Barthum Y, Melamed E, Roditi Y, Djaldetti R (2012) Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain 16:1243–1250.

Grover S, Kumar V, Chakrabarti S, Hollikatti P, Singh P, Tyagi S, Kulhara P, Avasthi A (2012) Prevalence and type of functional somatic complaints in patients with first-episode depression. East Asian Arch Psychiatry 22:146–153.

Gutierrez T, Nackley AC, Neely MH, Freeman KG, Edwards GL, Hohmann AG (2003) Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antino- ciception in models of acute and tonic nociception. Brain Res 987:176–185.

Haj-Dahmane S, Shen RY (2011) Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology 61:414–420.

Haller J, Matyas F, Soproni K, Varga B, Barsy B, Nemeth B, Mikics E, Freund TF, Hajos N (2007) Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 25:2445–2456.

Hanus L, Abu-Lafi S, Frade E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechemal R (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662–3665.

Hasnie FS, Wallace VC, Hefner K, Holmes A, Rice AS (2007) Mechanical and cold hypersensitivity in nerve-injured C57BL/6J mice is not associated with fear-avoidance- and depression-related behavior. Br J Anaesth 98:816–822.

Hasselt AI, Aquino JK, Ilgen MA (2014) The risk of suicide mortality in chronic pain patients. Curr Pain Headache Rep 18:436.

Hawker GA, Gignac MA, Badley E, Davis AM, French MR, Li Y, Perruccio AV, Power JD, Sale J, Lou W (2011) A longitudinal study to explain the pain-depression link in older adults with osteoarthritis. Arthritis Care Res (Hoboken) 63:1382–1390.

Henry RJ, Kerr DM, Finn DP, Roche M (2014) FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus. J Neuroinflamm 11:126–134.

Henry RJ, Kerr DM, Finn DP, Roche M (2015) For whom the endocannabinoid toils: modulation of innate immune function and implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry PMID: 25794989.

Herkenham M (1991) Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res Monogr 112:129–145.

Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in the brain. Proc Natl Acad Sci USA 87:1932–1936.

Hill MN, Gorzalka BB (2005) Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 16:333–352.

Hill MN, Tasker JC (2012) Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204:5–16.

Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB (2005) Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30:508–515.
Hill MN, Ho WS, Sinopoli KJ, Vieu V, Hillard CJ, Gorzalka BB (2006) Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31:2591–2599.

Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB (2008a) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106:2322–2336.

Hill MN, Ho WS, Hillard CJ, Gorzalka BB (2008b) Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm 115:1673–1679.

Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008c) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41:48–53.

Hill MN, McLaughlin RJ, Morrish AC, Vieu V, Floresco SB, Hillard CJ, Gorzalka BB (2009a) Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 34:2733–2745.

Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009b) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34:1257–1262.

Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT, Karatsoreos IN, Mackie K, Vieu V, Pickel VM, McEwen BS, Liu QS, Gorzalka BB, Hillard CJ (2011) Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 31:10506–10515.

Hillard CJ, Liu QS (2014) Endocannabinoid signaling in the etiology and treatment of major depressive illness. Curr Pharm Des 20:3795–3811.

Hu B, Doods H, Treede RD, Ceci A (2009) Depression-like behavior in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 143:206–212.

Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99:8400–8405.

Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153:1837–1846.

Imbe H, Kimura A, Donishi T, Kaneoke Y (2012) Chronic restraint stress decreases glial fibrillary acidic protein and glutamate transporter in the periaqueductal gray matter. Neuroscience 223:209–218.

Ishikawa K, Yasuda S, Fukuhara K, Iwanaga Y, Ida Y, Ishikawa J, Yamagata H, Ono M, Kakeda T, Ishikawa T (2014) 4-Methylcatechol prevents derangements of brain-derived neurotrophic factor and TrkB-related signaling in anterior cingulate cortex in chronic pain with depression-like behavior. Neuroreport 25:226–232.

Jennings EM, Okine BN, Olango WM, Roche M, Finn DP (2015) Repeated forced swim stress differentially affects formalin-evoked nociceptive behavior and the endocannabinoid system in stress normo-responsive and stress hyper-responsive rat strains. Prog Neuropsychopharmacol Biol Psychiatry PMID: 25985529.

Jennings EM, Okine BN, Roche M, Finn DP (2014) Stress-induced hyperalgesia. Prog Neurobiol 121:1–18.

Jentsch JD, Andrusiak E, Tran A, Bowers MB Jr, Roth RH (1997) Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 16:426–432.

Jesse CR, Wilhelm EA, Nogueira CW (2010) Depression-like behavior and mechanical allodynia are reduced by bis selenium treatment in mice with chronic constriction injury: a comparison with flouxetine, amitriptyline, and bupropion. Psychopharmacology (Berl) 212:513–522.

Ji G, Fu Y, Ruppert KA, Neugebauer V (2007) Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala. Mol Pain 3:13.

Johnson AC, Tran L, Schulkin J, Greenwood-Van Meerveld B (2012) Importance of stress receptor-mediated mechanisms in the amygdala on visceral pain perception in an intrinsically anxious rat. Neurogastroenterol Motil 24:479–486, e219.

Juhasz G, Lazary J, Chase D, Pegg E, Downey D, Toth ZG, Stones K, Platt H, Mekli K, Payton A, Anderson JM, Deakin JF, Bagdy G (2009) Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett 461:116–120.

Kadetoff D, Lamp A, Westman M, Andersson M, Kosek E (2012) Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 242:33–38.

Kappelman MD, Long MD, Martin C, DeWalt DA, Kinneer PM, Chen W, Lewis JD, Sandler RS (2014) Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12:1315–1323 e1312.

Katon I, Rancz EA, Acasdy L, Ledent C, Mackie K, Hajas N, Freund TF (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21:9506–9518.

Katz PS, Sulzer JK, Impastato RA, Teng SX, Rogers EK, Molina PE (2015) Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. J Neurotrauma 32:297–306.

Kaufmann I, Hauer D, Hong V, Vogeser M, Campolongo P, Chouker A, Thiel M, Schelling G (2009) Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. Eur Surg Res 43:325–329.

Kendall SF, Krystal JH, Sanacora G (2005) GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 9:153–168.

Kerr DM, Burke NN, Ford GK, Connor TJ, Harhen B, Egan LJ, Finn DP, Roche M (2012) Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 204:53–63.

Kerr DM, Harhen B, Okine BN, Egan LJ, Finn DP, Roche M (2013) The monoacylglycerol lipidase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol 169:808–819.

Khongsaengdao B, Louthrenoo W, Srisurapanont M (2000) Depression in Thai patients with rheumatoid arthritis. J Med Assoc Thai 83:743–747.
Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, Rusanescu G, Yang L, Tian Y, Mao J (2012) Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 122:2940–2954.

Kim J, Li Y (2015) Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission. J Physiol 593:871–886.

Kirily E, Huruyda L, Bagdy G (2013) Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists. J Neural Transm 120:177–186.

Knaster P, Karlsson H, Estlander AM, Kalso E (2012) Psychiatric disorders as assessed with SCID in chronic pain patients: the anxiety disorders precede the onset of pain. Gen Hosp Psychiatry 34:46–52.

Knerlich-Lukoschus F, Noack M, von der Ropp-Brenner B, Lucas R, Mehldorn HM, Held-Feindt J (2011) Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. J Neurotrauma 28:619–634.

Knuth B, Radtke V, Rocha P, da Silva KS, Dalsoglio F, Giesen HJ, Wolf A, Freynhagen R (2007) Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients. Inflamm Res 56:32–37.

Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood and addiction. Neuroscience 250:12–20.

Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood and addiction. Neuroscience 250:12–20.

Kontinen VK, Kauppila T, Paananen S, Pertovaara A, Kalso E (1999) Behavioral measures of depression and anxiety in rats with spinal nerve ligation-induced neuropathy. Pain 80:341–346.

Kozak KR, Rowlinson SW, Marnett LJ (2000) Oxyxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275:33744–33749.

Lambrecht BM, Kappel M, Renné T, Engelhardt J, Hansson M, Kallinowski F, Kubes P, Nolte K-H, Finkbeiner S, Kolb HJ, Hainfellner JA, O'Sullivan J, Kubes P, Nolte K-H, Finkbeiner S, Kolb HJ, Hainfellner JA, O’Neill LAJ, Mucida D, Bollard C, Schindler C, O’Connell MJ, Hooper L (2015) Endocannabinoid system controls neutrophil migration and tissue damage in chronic inflammation. Nature 519:399–403.

Layton KA, Bylund SD, Haddad R, Hoekstra D, Zhang Y, Willard C, Tian Y, Mao J (2015) Experimental stress induces hyperalgesia in an animal model of chronic pain. J Neurosci 35:1268–1273.

Lee AM, Lee M, Su C, Zou A, Wang J (2014) AMPAkines have novel analgesic effects in rat models of persistent neuropathic and inflammatory pain. Anesthesiology 121:1080–1090.

Lee MC, Ploner M, Wieck K, Bingel U, Wanigasekera V, Brooks J, Menon DK, Tracey I (2013) Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154:124–134.

Leggett JD, Aspley S, Beckett SR, D’Antona AM, Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141:253–262.

Li JX (2015) Pain and depression comorbidity: a preclinical perspective. Behav Brain Res 272:92–98.

Lim G, Sung B, Ji RR, Mao J (2003) Upregulation of spinal cannabinoid-1 receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105:275–283.

Lin MC, Guo HR, Lu MC, Livneh H, Lai NS, Tsai TY (2015) Increased risk of depression in patients with rheumatoid arthritis: a seven-year population-based cohort study. Clinics (Sao Paulo) 70:91–96.

Liu SB, Zhao R, Li XS, Guo HJ, Tian Z, Zhang N, Gao GD, Zhao MG (2014) Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice. Neuroulemic Med 16:350–359.

Lockie SH, Czyzyn TA, Chaudhary N, Perez-Tilve D, Woods SC, Oldfield BJ, Statnick MA, Tschop MH (2011) CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice. Endocrinology 152:3661–3667.

Lomazzo E, Bindila L, Remmers F, Lerner R, Schwitzer C, Hoheisel U, Lutz B (2015) Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. Neuropsychopharmacology 40:488–501.

Lu C, Liu Y, Sun B, Sun Y, Hou B, Zhang Y, Ma Z, Gu X (2015) Intrathecal injection of JWH-015 attenuates bone cancer pain via time-dependent modification of pro-inflammatory cytokines expression and astrocytes activity in spinal cord. Inflammation PMID: 25896633.

Ludwig J, Binder A, Steinmann J, Wasner G, Baron R (2008) Cytokine expression and astrocytes activity in spinal cord injury. Trends Neurosci 31:903–908.

Luo J, Wang T, Liang S, Hu X, Li W, Jin F (2013) Experimental gastritis leads to anxiety- and depression-like behaviors in female but not male rats. Behav Brain Funct 9:1–12.

Maido V, Ennis M, Irani S, Corbo M, Dolzhikov M (2008) Adjunctive nabirole in cancer pain and symptom management: a prospective study. Pain Res Treat 2008:877227.

Mackie K (2008) Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20 Suppl 1:10–14.

Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011) The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:702–721.

Maida V, Ennis M, Irani S, Corbo M, Dolzhikov M (2008) Adjunctive nabirole in cancer pain and symptom management: a prospective study. Pain Res Treat 2008:877227.
prospective observational study using propensity scoring. J Support Oncol 6:119–124.

Maletic V, Raison CL (2009) Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci (Landmark Ed) 14:5291–5338.

Maneeton N, Maneeton B, Srisurapanont M (2013) Prevalence and predictors of pain in patients with major depressive disorder. Asian J Psychiatr 6:288–291.

Manning BH, Martin WJ, Meng ID (2003) The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience 120:1157–1170.

Marco EM, Echeverry-Alzate V, Lopez-Moreno JA, Gine E, Penasco S, Viveros MF (2014) Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. Behav Pharmacol 25:547–556.

Marcic NP, Adzic M (2013) Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits. Psychiatr Danub 25:299–305.

Mato S, Vidal R, Castro E, Diaz A, Pazos A, Val dizan EM (2010) Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol Pharmacol 77:424–434.

Matsuda LA, Loliat SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564.

McLaughlin RJ, Hill MN, Bambico FR, Stuhrl KL, Gobbi G, Hillard CJ, Gorzalka BB (2012) Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur Neuropsychopharmacol 22:664–671.

McLaughlin RJ, Hill MN, Dang SS, Wainwright SR, Galea LA, Hillard CJ, Gorzalka BB (2013) Upregulation of CB(1) receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res 237:333–337.

Menchoulam R, Ben-Shabat S, Hansu L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90.

Meerwijk EL, Ford JM, Weiss SJ (2013) Brain regions associated with psychological pain: implications for a neural network and its relationship to physical pain. Brain Imaging Behav 7:1–14.

Mellis M, Pistas M (2012) Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci 367:3276–3285.

Meng ID, Manning BH, Martin WJ, Fields HL (1998) An alganesia circuit activated by cannabinoids. Nature 395:381–383.

Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355–474.

Miller LL, Pickler MJ, Schmidt KT, Dykstra LA (2011) Effects of morphine on pain-elicted and pain-suppressed behavior in CB1 knockout and wildtype mice. Psychopharmacology (Berl) 215:455–465.

Miller LL, Pickler MJ, Umenberger MD, Schmidt KT, Dykstra LA (2012) Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicted and pain-suppressed behavior in mice. J Pharmacol Exp Ther 342:177–187.

Minocchi D, Massei J, Martino A, Milianti M, Piz L, Di Bello D, Sbrana A, Martinotti E, Rossi AM, Nieri P (2011) Genetic association between bipolar disorder and 524A>C (Leu133lle) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. J Affect Disord 134:427–430.

Mitjans M, Gasto C, Catalan R, Fananas L, Arias B (2012) Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes. J Psychopharmacol 26:1391–1398.

Mitjans M, Serretti A, Fabbri C, Gasto C, Catalan R, Fananas L, Arias B (2013) Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology (Berl) 227:509–519.

Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuky U, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I (2006) Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126:102–114.

Monteleone E, Bifulco M, Maina G, Tortorella A, Gazzzerro P, Proto MC, Di Filippo C, Monteleone F, Canestrelli B, Buonarba G, Bogetto F, Maj M (2010) Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 61:400–404.

Moranta D, Esteban S, Garcia-Sevilla JA (2009) Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulates the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn Schmiedebergs Arch Pharmacol 379:61–72.

Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65.

Naderi N, Shafaghi B, Khodayar MJ, Zarindast MR (2005) Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat. Eur J Pharmacol 514:159–164.

Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh AM, Khani A, Motamedi F (2008) Interaction between cannabinoid compounds and diazepam on anxiety-like behavior of mice. Pharmacol Biochem Behav 89:64–75.

Nagakura Y, Oe T, Aoki T, Matsuoka N (2009) Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 146:26–33.

Narita M, Kaneko C, Miyoshi K, Nagumo Y, Kuzumaki N, Nakajima M, Nanjo K, Matsuzawa K, Yamazaki M, Suzuki T (2006) Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31:739–750.

Navarra A, Tamburella A, Iannotti FA, Micale V, Camillieri G, Gazzo L, Verde R, Imperatore R, Leggio GM, Drago F, Di Marzo V (2014) The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. Pharmacol Res 87:151–159.

Nicholl BI, Mackay D, Cullen B, Martin DJ, Ul-Haq Z, Mair FS, Evans J, McIntosh AM, Gallagher J, Roberts B, Deary IJ, Fell JP, Smith DJ (2014) Chronic multisite pain in major depression and bipolar disorder: cross-sectional study of 149,611 participants in UK Biobank. BMC Psychiatry 14:350.

Nogueira JB, Sena LC, Quintans Jde S, Almeida JR, Franca AV, Junior LJ (2012) Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit. J Pharm Ther 11:5–15.

Norman GJ, Karelima K, Zhang N, Walton JC, Morris JS, Devries AC (2010) Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury. Mol Psychiatry 15:404–414.

Nunez E, Benito C, Pazos MR, Barbachano A, Fajardo O, Gonzalez S, Tolon RM, Romero J (2004) Cannabinoid CB2 receptors
are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53:208–213.

O’Malley D, Julio-Pieper M, Gibney SM, Dinan TG, Cryan JF (2010) Distinct alterations in colonic morphology and physiology in two rat models of enhanced stress-induced anxiety and depression-like behavior. Stress 13:114–122.

Orpezan AC, Page ME, Van Bockstaele EJ (2005) Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 1046:45–54.

Osei-Hyiaman D, DePetrillo M, Facher P, Liu J, Radaeva S, Bata S, Harvey-White J, Mackie K, Offerterl L, Wang L, Kunos G (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298–1305.

Overtone HA, Babb AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Proctor MJ, Rassamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reyent C (2006) Deorphanization of a G protein-coupled receptor for oleoylthanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3:167–175.

Page ME, Orpeza VC, Sparks SE, Qian Y, Menko AS, Van Bockstaele EJ (2007) Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav 86:162–168.

Page ME, Orpeza VC, Van Bockstaele EJ (2008) Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett 431:1–5.

Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano DK, Di Marzo V, Mangoni GS, Rossi F, Maione S (2006) Neuro-pathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 24:2011–2020.

Pare WP, Redei E (1993) Depressive behavior and stress ulcer in Wistar Kyoto rats. J Physiol Paris 87:229–238.

Parent AJ, Beaudet N, Beaudry H, Bergeron J, Berube P, Drolet G, Sarret P, Gendron L (2012) Increased anxiety-like behaviors in rats experiencing chronic inflammatory pain. Behav Brain Res 229:160–167.

Park JM, Choi MG, Cho YK, Lee IS, Kim SW, Choi KY, Chung IS (2011) Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study. J Clin Gastroenterol 45:45–49.

Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145:5431–5438.

Pellkofer HL, Havlja J, Hauer D, Schelling G, Azad SC, Kuempfel T, O’Malley D, Julio-Pieper M, Gibney SM, Dinan TG, Cryan JF (2010) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020–1024.

Prescott SM, Majerus PW (1983) Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J Biol Chem 258:764–769.

Quintero L, Cardenas R, Suarez-Rocha H (2011) Stress-induced hyperalgesia is associated with a reduced and delayed GABA inhibitory control that enhances post-synaptic NMDA receptor activation in the spinal cord. Pain 152:1909–1922.

Racz I, Nent E, Erxele E, Zimmer A (2015) CB1 receptors modulate affective behavior induced by neuropathic pain. Brain Res Bull 114:42–48.

Rani Sagar D, Burston JJ, Woodhams SG, Chapman V (2012) Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci 367:3300–3311.

Rea K, Roche M, Finn DP (2007) Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol 152:633–648.

Rea K, Olango WM, Okine BN, Madasu MK, McGuire JC, Coyle K, Harben B, Roche M, Finn DP (2014) Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. Pain 155:69–79.

Reich CG, Mihalik GR, Iskander AN, Seckler JC, Weiss MS (2013) Adolescent chronic mild stress alters hippocampal CB1 receptor-mediated excitatory neurotransmission and plasticity. Neuroscience 253:444–454.

Reich CG, Taylor ME, McCarthy MM (2009) Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behav Brain Res 203:264–269.

Rey AA, Purrio M, Viveros MP, Lutz B (2012) Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37:2624–2634.

Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett R, Kendall DA, Scammell BE, Reeve AJ, Chapman V (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10:843.

Riebe CJ, Wotjak CT (2011) Endocannabinoids and stress. Stress 14:384–397.

Rivat C, Becker C, Blugeot A, Zeau B, Mauborgne A, Pohl M, Benoliel JJ (2010) Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia. Pain 150:358–368.

Roberts CJ, Stuhrl KL, Hutz MJ, Raff H, Hillard CJ (2014) Endocannabinoid signaling in hypothalamic-pituitary-adenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. Pharmacol Biochem Behav 117:17–24.

Roberts JD, Cennings C, Shih M (2006) Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530:54–58.

Roche M, Finn DP (2010) Brain CB2 Receptors: implications for neuropsychiatric disorders. Pharmaceuticals 3:2517–2533.

Rock RB, Gekker G, Hu S, Sheng WS, Cabral GA, Martin BR, Peterson PK (2007) WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmun Pharmacol 2:178–183.

Rodriquez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21:823–833.
An altered spinal serotonergic system contributes to increased thermal nociception in an animal model of depression. Exp Brain Res 232:1753–1803.

Preservation of striatal cannabinoid CB1 receptor function correlates with the antiinflammatory effects of fatty acid amide hydrolase inhibition. Mol Pharmacol 78:260–268.

The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101.

CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 12:3689–3692.

Seif T, Makiyannis A, Kunos G, Bonci A, Hopf FW (2011) The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience 193:21–33.

Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 33:128–130.

Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms. Brain Res Bull 86:118–122.

Depression shows divergent effects on evoked and spontaneous pain behaviors in rats. J Pain 11:219–229.

Nabilone for the treatment of pain in fibromyalgia. J Pain 9:164–173.

Anandamide and N-acylethanolamines in rat brain structures. Neurotox Res 26:190–206.

Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinoceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571:129–137.

Anandamide alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 98:408–419.

Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:760–768.

Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA 274:1511–1517.

Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33:54–67.

Decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:760–768.

Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA 274:1511–1517.

Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33:54–67.

Reduced GABA neurotransmission underlies hyperalgesia induced by repeated forced swimming stress. Behav Brain Res 189:159–169.

The interplay of inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. Neuropsychopharmacology 96(A):105–112.

The endocannabinoid system as a potential therapy in major depressive disorder. Psychopharmacology 218:113–117.

The relationship between pain, disability, quality of life and cognitive-behavioral factors in chronic back pain. Disabil Rehabil 34:1993–2000.

The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101.

The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101.

The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. Neuropsychopharmacology 96(A):105–112.

The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. Neuropsychopharmacology 96(A):105–112.

The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. Neuropsychopharmacology 96(A):105–112.
donoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45:3709–3720.

Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A (2005) Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 29:358–367.

Yalcin I, Bohren Y, Wulsperger E, Sage-Ciocca D, Yin JC, Freund-Mercier MJ, Barrot M (2011) A time-dependent history of mood disorders in a murine model of neuropathic pain. Biol Psychiatry 70:946–953.

Yalcin I, Barthas F, Barrot M (2014) Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci Biobehav Rev 47:154–164.

Yasuda S, Yoshida M, Yamagata H, Iwanaga Y, Suenaga H, Ishikawa K, Nakano M, Okuyama S, Furukawa Y, Furukawa S, Ishikawa T (2014) Imipramine ameliorates pain-related negative emotion via induction of brain-derived neurotrophic factor. Cell Mol Neurobiol 34:1199–1208.

Yu M, Ives D, Ramesha CS (1997) Synthesis of prostaglandin E2 ethanlamide from anandamide by cyclooxygenase-2. J Biol Chem 272:21181–21186.

Zajkowska ZE, Englund A, Zunszain PA (2014) Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. Pharmacogenomics 15:687–698.

Zavitsanou K, Wang H, Dalton VS, Nguyen V (2010) Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats. Neuroscience 169:315–324.

Zeng Q, Wang S, Lim G, Yang L, Mao J, Sung B, Chang Y, Lim JA, Guo G (2008) Exacerbated mechanical allodynia in rats with depression-like behavior. Brain Res 1200:27–38.

Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, Gardner EL, Wu J, Xi ZX (2014) Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A 111:E5007–E5015.

Zhang J, Hoffert C, Yu HK, Groblewski T, Ahmad S, O'Donnell D (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17:2750–2754.

Zhang M, Dai W, Liang J, Chen X, Hu Y, Chu B, Pan M, Dong Z, Yu S (2013) Effects of UCMS-induced depression on nociceptive behaviors induced by electrical stimulation of the dura mater. Neurosci Lett 551:1–6.

Zhang Z, Wang W, Zhong P, Liu SJ, Long JZ, Zhao L, Gao HQ, Cravatt BF, Liu QS (2015) Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. Hippocampus 25:16–26.

Zhao X, Wang C, Zhang JF, Liu L, Liu AM, Ma Q, Zhou WH, Xu Y (2014) Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABAA receptor. Psychopharmacology (Berl) 231:2171–2187.

Zhang H, Wang W, Pan B, Liu X, Zhang Z, Long JZ, Zhang HT, Cravatt BF, Liu QS (2014) Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 39:1763–1776.

Zhou W, Dantzer R, Budac DP, Walker AK, Mao-Ying QL, Lee AW, Heijnen CJ, Kavelaars A (2015) Peripheral indoleamine 2,3-dioxygenase 1 is required for comorbid depression-like behavior but does not contribute to neuropathic pain in mice. Brain Behav Immun 46:147–153.

Zoppiti S, Madrigal JL, Caso JR, Garcia-Gutierrez MS, Manzanares J, Leza JC, Garcia-Bueno B (2014) Regulatory role of the can-
nabinoid CB2 receptor in stress-induced neuroinflammation in mice. Br J Pharmacol 171:2814–2826.
Zoppi S, Perez Nievas BG, Madrigal JL, Manzanares J, Leza JC, Garcia-Bueno B (2011) Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology 36:805–818.
Zunszain PA, Hepgul N, Pariante CM (2013) Inflammation and depression. Curr Top Behav Neurosci 14:135–151.